Floatz logo

MICAFUNGIN

Morbid Obesity

Radboud University Medical CenterSmall moleculePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
81/ 100

Competitive context

66 Active assets in the Morbid Obesity cohort.

Asset / SponsorPhaseRating
LIDOCAINE
Instituto Mexicano del Seguro Social
Phase 4BBB
Colesevelam
Hvidovre University Hospital
Phase 4BBB
RAMIFENTANYL
Hospital dos Lusíadas
Phase 4BBB
Chenodeoxycholic Acid
Hvidovre University Hospital
Phase 4BBB
PROPOFOL
G.Gennimatas General Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

MICAFUNGIN is also rated in:

nutritional deficiency diseaseDormant
B
Indicative ·
61 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
Febrile NeutropeniaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →